drug-discovery

Only got two mins? The drug repurposing approach to drug discovery for neglected diseases has shown to be effective to find potential therapeutic agents. For Chagas disease, in particular, with some of these agents even making it to clinical trials. We have shown that a programmatic approach for drug repurposing, using intensive chemogenic data integration strategies, can recall known bioactive compounds and druggable targets for a selected pathogen species, and can also recommend novel drug-target pairs for further experimental validation (Berenstein et al, 2016).

A common strategy to identify new antiparasitic agents is the targeting of proteases, due to their essential contributions to parasite growth and development. Metacaspases (MCAs) are cysteine proteases present in fungi, protozoa, and plants. These …

Computational repositioning of bioactive compounds from large chemogenomic screens: identification of conserved druggable modules between yeasts and trypanosomes

Mind the gap: Bridging the knowledge rift between model organisms and pathogens causing neglected diseases

TDR Targets, a chemogenomics resource for Neglected Diseases

Identification and repurposing of bioactive compounds for Chagas disease: combining chemogenomics with high-throughput phenotypic screening

Data integration for target prioritization and drug discovery or repurposing

Identification of the first inhibitors and chemical tools for the M32 family of carboxypeptidases

A recap on updates & updagrades for TDR Targets chemogenomics resource to aid on drug discovery, repurposing and develeopment for neglected diseases

American Trypanosomiasis or Chagas disease is a prevalent, neglected and serious debilitating illness caused by the kinetoplastid protozoan parasite Trypanosoma cruzi. The current chemotherapy is limited only to nifurtimox and benznidazole, two drugs …